Introduction
Effective stroke prevention in patients with atrial fibrillation (AF) requires the use of oral anticoagulation. In the historical randomized trials, the use of warfarin significantly reduced the risk of stroke (by 64%) and all-cause mortality (by 26%) when compared with placebo or control. 1 However, the effectiveness and safety of warfarin is dependent upon the quality of anticoagulation control (time in therapeutic range [TiTR]) 2 even in the presence of a single stroke risk factor. 3 Optimization of TiTR is dependent on many factors and the most common are included in the SAMe-TT 2 R 2 score. 4 This score has been validated to aid clinical decision-making and has been shown to be predictive of labile INRs, bleeding, thromboembolism, and death, consequences of poor anticoagulation control. [5] [6] [7] [8] In the ENSURE-AF study, the oral factor Xa inhibitor edoxaban was compared to warfarin in 2199 patients undergoing electrical cardioversion of non-valvular AF. 9 Ideal patient management requires optimization of warfarin therapy within a therapeutic range of international normalized ratio (INR) 2.0-3.0, especially in the peri-cardioversion period. Given the prospectively collected data in ENSURE-AF, we determined aspects of anticoagulation control in the warfarin arm of this randomized trial, in an ancillary analysis.
Methods
The design and principal results of the ENSURE-AF trial (NCT 02072434) have been published. 9 The primary efficacy analysis was comparing the occurrence of a composite endpoint of stroke, systemic embolic event (SEE), myocardial infarction (MI), and cardiovascular death (CVD) between the edoxaban group and the enoxaparin-warfarin group from randomization to end of follow-up and was performed on the intention-to-treat population (all individuals who were enrolled into the study and randomly assigned). The primary safety endpoint of the trial was the composite of major + clinically relevant non-major (CRNM) bleeding which occurred during the on treatment period, defined as the time period the patient was taking study medication plus up to 3 days after the last dose for that time period. Any bleeding was defined as the composite of major + CRNM + minor bleeding from time of first administration of study drug to end of treatment +3 days. Patients were followed for 28 days on study drug after cardioversion + another 30 days to assess safety on an investigator-prescribed standard of care.
The protocol and its amendments were approved by ethics committees or institutional review boards. All patients provided written informed consent prior to participation in the study. TiTR data were dichotomized to show the relation of TtTR and TiTR to efficacy and safety outcomes.
Odds ratios (ORs) and 95% confidence intervals (CIs) are presented.
Efficacy and safety outcomes were compared between the patients who received enoxaparinwarfarin and patients who received edoxaban from sites with mean TiTR ≤70% and >70%, respectively.
Results
Among 1104 patients randomized to enoxaparin-warfarin, 27% were naïve to OAC at randomization ( Table 3 ]. Figure 1 illustrates these efficacy and safety outcomes in relation to TiTR.
Discussion
In this pre-specified analysis of a well-managed cohort of warfarin users in a clinical trial setting we found that the only independent determinant of TtTR was CrCl, while independent predictors of TiTR were prior VKA experience and low HAS-BLED score. Additionally, in this cohort with a high TiTR (>70%), 7 no difference was observed between mean TtTR and TiTR in regards to the SAMe-TT 2 R 2 score.
Nevertheless, even in this short-term study, TiTR was related to bleeding events.
We found that an independent predictor of TtTR was CrCl, consistent with prior data showing the difficulties of managing warfarin in non-valvular AF patients with renal impairment. 14 versus those less likely to achieve good TiTR (SAMe-TT 2 R 2 score >2). 6, 17 Furthermore, the validated SAMe-TT 2 R 2 score is predictive of labile INRs, as well as the adverse outcomes associated with poor anticoagulation control, such as thromboembolism, death and bleeding. 8 Nonetheless, in this cohort with a high TiTR (>70%), the SAMe-TT 2 R 2 score did not discriminate between mean TtTR and TiTR.
Similar findings were noted in another observational cohort with high TiTR, 18 although the short followup and meticulous attention to achieving good TiTR may have reduced the predictive value of SAMe- Time to therapeutic range was not significantly related to stroke/SEE/MI/CVD or any bleeding, and this may reflect the ENSURE-AF trial design, where enoxaparin bridging was used in patients wherever
INRs were suboptimal to allow optimized warfarin management to be compared with edoxaban. 9 Also, the short follow-up in this relatively low risk population of patients with non-valvular AF selected for cardioversion may have influenced event rates. However, even in this cohort with high TiTR, there was a significant relation of TiTR to any bleeding, but not stroke/SEE/MI/CVD. The non-significant impact on the latter may reflect the low overall event rates in the trial, and the short follow-up period.
Nonetheless, TiTR is also a strong determinant of bleeding risks on VKA, and our data support this relationship.
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Although the ENSURE-AF trial is the largest study in AF peri-cardioversion to date, this study is limited by being a subgroup analysis of a selected clinical trial cohort, and the results may not be applicable to the general AF population. In the 'real world', adherence and quality of life on enoxaparin injections would be relevant considerations, but we mandated good adherence in this trial setting. Also, the low overall event rates and short follow-up period may have influenced outcome rates which may be underpowered. In the trial setting, much focus was made towards achieving good TTR (which was achieved, with TiTR >70%) and would not be reflective of 'real world' warfarin management in some healthcare settings.
The high rate of patients not achieving therapeutic range reflects the short nature of follow-up (28 days post-cardioversion plus 30 additional days), but we ensured adequate anticoagulation was administered by enoxaparin bridging to ensure no delays in cardioversion. 9 In this well-managed cohort of warfarin users with documented non-valvular AF in a clinical trial setting with a high TiTR (>70%), no difference was seen between TtTR and TiTR in relation to SAMe-TT 2 R 2 score. Even in this short term study, TiTR was significantly related to bleeding events.
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